Posted by Michael Wonder on 21 Jan 2026
LBL-024 (opamtistomig PD-L1/4-1BB bispecific antibody) granted fast track designation by the US FDA
14 January 2026 - The Company is pleased to announce that LBL-024 (opamtistomig), a PD-L1/4-1BB bispecific antibody, was granted fast track designation by the US FDA for the treatment of extra-pulmonary neuroendocrine carcinoma on 14 January 2026.
LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB.
